Assessment of pharmaceutical services in HIV/AIDS health units in the city of Niterói, Brazil by Piccoli, Nilo Jorge et al.
Braz. J. Pharm. Sci. 2017;53(2):e16113 Page 1 / 10
Brazilian Journal of 
Pharmaceutical Sciences
http://dx.doi.org/10.1590/s2175-97902017000216113
A
rt
ic
le
*Correspondence: S. R. Castilho. Departamento de Farmácia e Administração 
Farmacêutica. Universidade Federal Fluminense. Rua Marquês do Paraná, 282, 
24030-211, Niterói, RJ, Brasil. E-mail: selmarc@id.uff.br
Assessment of pharmaceutical services in HIV/AIDS health units in 
the city of Niterói, Brazil
Nilo Jorge Piccoli1, Monique Araújo de Brito1,2, Selma Rodrigues de Castilho1,2,*
1Pharmaceutical Assistance Management Master Course, Fluminense Federal University, Niterói, RJ, Brazil, 2Department of 
Pharmacy and Pharmaceutical Management, Federal Fluminense University, Niterói, RJ, Brazil
This study aimed to conduct an assessment of pharmaceutical services in HIV/AIDS in the city of Niteroi, 
Brazil, with emphasis on management. It was done a descriptive cross-sectional study, and the approach 
used was a normative assessment focused on quality. The indicators used were analyzed individually 
or grouped according to the components of pharmaceutical services. The assessment identified some 
good points, especially regarding the good availability of ARVs, and good guide patients in the use of 
these drugs, and also some problems such as low levels of compliance in relation to good dispensing 
practices criteria and storage and a high time for the distribution of medicines. The result was a degree 
of 50.3% compliance with the quality criteria, considered only regular in accordance with trial made. 
Proposals were suggested for actions and interventions, especially in relation to the improvement of 
structural conditions of pharmacies of health facilities in the city, and increased training of professionals 
involved in the services.
Uniterms: Pharmaceutical assistance/evaluation. Pharmaceutical assistance/Brazil. Brazilian public 
health system/assistance/HIV/AIDS.
INTRODUCTION 
Brazilian Law No. 9313, enacted on November 13, 
1996, grants all individuals with HIV infection the right 
to free receipts for all Antiretroviral Medications (ARV) 
needed (Brasil, 1996). The results from the implementation 
of this law made  the Brazilian’s AIDS patients’ assistance 
program a world reference. Among its achievements we 
should point that, between 1997 and 2003, there was a 
40-70% mortality reduction, a reduction in morbidity of 
over 60%, and a ten-fold increase in survival after an AIDS 
diagnosis (Lago, Costa, 2010).
From a political point-of-view, the approval of this 
law was a major achievement for the social movements, 
although, from its start both the large investment in a 
disease with a low number of patients - at the expense 
of other more frequent or urgent ones - as the lack 
of infrastructure to manage drug distribution and 
dispensation, with the risk of no patient compliance, 
were questioned. (Lago, Costa, 2010). This challenge 
increased at the end of 2013, with the recommendation 
of the early use of ARV for all people living with HIV/
AIDS (PLWHA), regardless of their CD4 count, which 
resulted in an increase in the use of these medications in 
the country (Brasil, 2013).
Despite the obvious health and social benefits of 
this policy, sustainability has always been threatened by 
it, due its high cost of implementation and execution. 
Several factors contribute to higher spending, such as the 
growing number of patients and demands for newer drugs 
(in general caused by the emergence of viral resistance) 
that are protected by patents and are usually imported 
(Lago, Costa, 2010).
Various strategies have been employed by the 
Brazilian Department of Health to reduce these costs, such 
as the centralised acquisition of ARVs, the encouragement 
of domestic production, and compulsory licensing and 
price negotiations with producers. (Loyola, 2008; Lago, 
Costa, 2010).
In this scenario of rising costs, ensuring the access to 
antiretroviral drugs, the pharmaceutical services for HIV/
AIDS had to be strengthened (Brasil, 2010). Even today, 
the efficient management of pharmaceutical services in all 
its aspects and components is vital to the success of the 
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Brazilian HIV/AIDS program, allowing greater control 
over spending on ARVs and seeking effectiveness in the 
use of these products, especially through the pursuit of 
their rational use.
In this paper, it is assumed that access to medicine 
is “the relationship between the need for drugs and their 
supply, in which this need is met at the time and place 
required by the patient (consumer), with quality assurance 
and sufficient information for proper use” (Oliveira et al., 
2002). Therefore, access is the availability plus quality 
and information.
In the Brazilian program to assist patients with 
HIV/AIDS, the stages of selection, scheduling and 
procurement of drugs, management, financing, and 
monitoring of the production of drugs are the sole 
responsibility of the Department of Health. In the case 
of storage and distribution the responsibility is shared 
between the Department of Health, Brazilian states and 
cities, leaving the steps of prescription and dispensing 
under the responsibility of the so-called Medication 
Dispensing Units (UDMs), which can be federal, state or 
municipal institutions, but under the coordination of City 
Administrations. Human resources management is the 
responsibility of all the domains involved, according to 
the activity performed (Brasil, 2010).
Local quality problems can, however, compromise 
the national programme. According to Portela and 
Lotrowka (2006), one should reflect on the quality of 
the care in a specific-focus programme, but not without 
strengthening the Brazilian health system as whole, as 
regional problems could affect the standards intended for 
the services. 
In this program, not only the problems with drug 
supplying, but also in the process of storing, transporting 
and dispensing them, which increase the possibility of 
therapeutic failures and poor adherence by patients, can 
compromise the entire process and waste the resources 
invested by the program.
In order to detect possible management problems 
in pharmaceutical services focused on AIDS, and 
consequently subsidize interventions to improve and solve 
critical issues, this paper carried out a descriptive study 
of the pharmaceutical services for HIV/AIDS patients in 
the city of Niterói.
Two questions guided the work: (i) are the structure 
and conditions of the existing work processes adequate to 
ensure the quality of pharmaceutical services for people 
living with HIV/AIDS (PHVA) care in the city, and (ii) are 
the structure and work processes adequate to ensure access 
to antiretroviral drugs for opportunistic infections and 
PHVA care in the city?
METHODS 
Delimitation of the study/-assessment approach 
A descriptive cross-sectional  study of the 
pharmaceutical services for HIV/AIDS patients was done 
in Niterói. The approach used was a normative assessment 
focused on quality, involving the analysis of structure, 
process and outcomes, as the valuation model proposed 
by Donabedian (1982). A logical and theoretical model 
was constructed for the development of multiple quality 
indicators. To that end, we conducted a literature review 
and applied experts’ (stakeholders) opinions. 
Local study / analysis units 
The city of Niterói is located in the state of Rio 
de Janeiro, Brazil. A total 3,212 AIDS cases were 
reported from 1983 to 2013 in Niterói, with 199 new 
cases in 2012 and 169 in 2013 (Brasil, 2013b). All 
patients are seen at eight public health units, where 
all the health care is available for HIV/AIDS patients, 
including the dispensing of ARVs. In October 2013 
a total 2,587 patients, including adults, children and 
pregnant women received ARVs for treatment and 24 for 
prophylaxis or occupational accidents (Brasil, 2013a).
Those medications were dispensed in eight Medicine 
Dispensing Units (UDM) of the city. 
Six UDMs coded 1-6 were evaluated in this work. 
One UDM was excluded from the survey as it did not 
authorize data collection in time. The other UDM was the 
pilot for the validation of data collection instruments, also 
being excluded from the analysis.
Construction of the assessment
The first step was the identification of pharmaceutical 
services in HIV/AIDS stakeholders, who were invited to 
participate in meetings aimed at defining the focus of the 
assessment. The next step was a logical model design to 
describe all the elements of the Pharmaceutical Services 
in HIV/AIDS in Niterói, showing their operation and the 
relationships and links between their components. The 
construction of this model was based on two pre-existing 
logical models, one proposed for a similar study (Oliveira 
et al., 2002) reality, and another proposed for the Brazilian 
public program named Basic Pharmacy (Cosendey, Hartz, 
Bermudez, 2003).
The logical model indicators were divided into four 
groups according to some components of pharmaceutical 
services (distribution, storage, and dispensing) under 
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the responsibility of a city, and one more component, 
called qualifying, added by the authors. Most of the 
indicators (17) were selected directly or adapted from the 
literature. Others (3) have been developed by the authors 
in conjunction with the stakeholders.
The Steakholders were pharmacists working in 
pharmaceutical care in HIV/AIDS in the municipality, 
both at UDM and in Pharmacy Coordination. The five 
experts who participated had all at least 10 years in the 
profession, and not less than five years of activity in the 
STD/AIDS program. Initially meetings were conducted 
with these professionals to define the assessment focuses 
on the perspective of management, as well as defining the 
logical model (adaptation of Oliveira models, 2002 and 
Cosendey, 2003). These experts were also asked to assign 
weights 1-3 (3 being more relevant) to each proposed 
indicator. The average value of the weights was considered 
in the Relevance matrix. 
Data collection 
Data was collected through structured interviews 
with all Pharmacists responsible for the UDM. In addition, 
direct observation of specific points with the aid of 
assessment instruments was performed. Some documents, 
such as prescriptions, maps and reports from the logistic 
control program of the Department of Health (SICLOM), 
were also analyzed. Information on the medicine 
dispensing process was obtained by questionnaires applied 
to the users. The data was acquired mostly in a prospective 
way. However, some indicators were calculated based 
on retrospective data, especially those related to medical 
prescriptions and distribution data.
To collect data on medicines availability indicators, 
four visits were made in the period of two months, with 
intervals of approximately 15 days between them. The end 
result was defined by the average of the four observations. 
Thus, we sought to avoid the limitation pointed out by 
Oliveira et al. (2002), in which the absence of a drug at a 
single moment could be a consequence of prior service to 
all users of that particular drug. 
To calculate the sample of users to be interviewed 
an absolute maximum error of 5% and a confidence 
level of 95% were considered. Based on the literature, 
we defined a minimum 15% orientation percentage in 
relation to the C4 indicator, and 85% for the C5 indicator 
(Luiza et al., 2006). The maximum expected number of 
users was set at 1,806 patients, the largest number of 
users served in October 2012, including the pilot unit. 
Thus, the sample of 154 patients, plus 8 in the pilot, was 
set.
The number of users to be interviewed in each UDM 
was obtained proportionally, considering the total number 
of expected users (1,806) and the total number of patients 
seen per unit in the same month (October 2012). The 
selection and management of patients within each UDM 
were done for convenience, using the number of interview 
days needed to achieve the number of patients established 
in each UDM.
Data analysis 
The data was tabulated using Microsoft Excel 
spreadsheets, Office 2007 and the Epiinfo Windows 
3.5.2 program. At first, the indicators were calculated for 
each UDM. The calculation of the overall score for each 
indicator was obtained by the arithmetic mean of the 
results obtained by each individual UDM. However, for 
the C4 and C5 indicators, the final result for the city was 
based on the results of all patients interviewed, depending 
on the numerical range of interviews in each unit.
For indicators extracted from the literature, the same 
standards proposed by the original work were adopted. 
For those indicators suggested or adapted by the author, 
the parameter was obtained by a consensus amongst five 
(5) experts, all pharmacists, with a minimum 10 years in 
the profession, and no less than 5 years’ activity in the 
sexuality transmited diseases – AIDS ‘program.
These experts were also asked to assign weights 
1-3 (3 being more relevant) to each proposed indicator. 
The average value of the weights was considered in the 
Relevance matrix. A score was then obtained for each 
indicator, as well as a general result of the evaluation. A 
Matrix analysis was obtained for each UDM and for the 
city as a whole.
The final score, which determined the degree for 
pharmaceutical services in HIV/AIDS quality, both for 
each UDM as for the county, was obtained by dividing 
the sum of the scores of each indicator by the maximum 
possible score for each indicator x 100.
We sought to further evaluate the quality of 
pharmaceutical services components. Thus, we considered 
the four components which form the logical model, and 
found the degree of quality of each separately, according 
to the specific indicators in each component, to identify if 
there were any differences in quality between them, and if 
any of them had major or minor weaknesses or so-called 
‘critical nodes’.
This work was submitted to the Ethics Committee in 
Research of the School of Medicine, Universidade Federal 
Fluminense, Niterói, Brazil, having obtained an assent 
number 277 020 on 20/05/2013.
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RESULTS AND DISCUSSION 
Logical model 
The logic model (Figure 1) used, incorporated to the 
models proposed by Oliveira et al. (2002) and Cosendey, 
Hartz and Bermudez (2003), the changes observed 
in the HIV/AIDS program, including the SICLOM 
implementation, as well as the so-called qualification 
component, suggested by Cosendey, Hartz and Bermudez 
(2003).
Indicator results 
Table I lists the average of the results obtained for 
each indicator, whereas Table II shows the judgment value 
matrix used in the study. 
Only one UDM was not using the SICLOM software 
in all the processes, obtaining a final result of 83% for this 
indicator. This result is higher than that found by Luiza et 
al. (2006) in which only 31% of those surveyed used the 
UDM SICLOM in the processes of inventory control. It 
is important to consider that this study was conducted in 
FIGURE 1 - Logic Model suggested for Pharmaceutical Services in HIV/AIDS in city of Niterói. (Adapted from Oliveira et al., 
2002 and Cosendey, Hartz, Bermudez, 2003)
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TABLE I - List of indicators used and results obtained (average results for UDM)
COMPONENT: DISTRIBUITION
Code Indicator / Name Calculation Standard Source Average Result
 A1 Percentage of use of the 
software SICLOM
Use or not of SICLOM 
software 100% Authors 83,0%
A2
Percentage of criteria 
for Good Practices in 
Transportation (GPT)
Number of items with GPT / 
number items (%)
100% Authors 25,0%
A3
Percentage of items in 
stock availability of ARV 
medications
Number in stock medicines 
/ medicines programmed 
number (%)
Above 95% Oliveira et al., 2002 Brasil, 2008 96,7%
A4
Percentage of items in stock 
availability of drugs for 
Opportunistic Infections
Number in stock medicines 
/ medicines programmed 
number (%)
Above 75% 
Oliveira et al., 2002 
Brasil, 2008 73,8%
A5 Frequency distribution
Time (in days) between the 
request and the delivery of 
drugs.
Maximum of 15 
days
Marin et al., 2003 
Luiza et al., 2006 25,2 days
A6
Availability of time for 
introducing new treatments or 
switching medications.
Time between the medical 
request and receipt by the 
patient
Same day Adapted of Brasil, 2008 Same day
A7
Availability of time for 
exchange of drugs in special 
situations (failure or exchange 
for prescription drugs not 
routinely)
Time between the medical 
request and receipt by the 
patient
Within 7 days Authors 10,6 days
COMPONENT: STORAGE
B1
Percentage of criteria for 
Good Practice in Storage 
(GPS)
Number of items with GPS / 
number items (%)
100%
Adaptaded of 
Oliveira et al., 2002 
and Marin et al., 
2003
73,7%
B2 Percentage of expired drugs
Number of active ingredients 
with expiration date overdue / 
Total active ingredients
0% Oliveira et al., 2002 0%
B3 Average percentage change in inventory
Calculate the difference 
between the physical and the 
record, the physical divide and 
multiply by 100.
Maximum of 5% 
(to more or less) Oliveira et al., 2002 14,8%
B4
Average percentage of the 
stock record that does not 
match the physical count for 
ARV drugs in stock
Number of items ranging 
outside the range between 
95-105% in relation to the 
inventory divided by the total 
number of items.
Maximum of 5% 
of the items.
Adaptaded of 
Oliveira et al., 2002 33,7%
COMPONENT: DISPENSING
C1
Percentage of criteria for 
Good Practice of Dispensing 
(GPD)
Number of items with GPD / 
number items (%)
100% Adaptaded of 
Oliveira et al., 2002 51,2%
C2
Utilization percentage of 
software OPERATIONAL 
SICLOM in procedures of 
dispensing
Number of UDM using the 
SICLOM in procedures 
dispensing / Total number of 
UDM
100% Adaptaded of Sakita, 2012 33,3%
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a different ciy (Rio de Janeiro) and at the beginning of the 
national program implementation.
The average score for the indicator of Good 
Transport Practice (GPT) was of only 25% (Standard 
Deviation (SD)=0.14), suggesting serious problems 
regarding drug transport. The vehicles used were not 
adequate in any of the UDM, including the fact that they 
had no conditions for the transport of labile drugs.
The mean availability in stock for ARV drugs was 
96.7% (SD=1.03). Other studies obtained similar results 
(Oliveira et al., 2002; Melchior et al., 2006), while a 
study had an average availability of 88% for these drugs 
(Luiza et al., 2006). We should point that those studies 
applied tracer medicines for availability check, whereas 
the present study evaluated the presence in the stock of all 
the medicines used by the UDM.
As regards the availability of drugs for opportunistic 
infections, the result (73.8%) (SD = 8.3) was much lower 
than that for the ARV. It should be noted that four data 
collections were considered to assess the availability in 
each UDM. The value obtained approximates the mean 
availability found by Luiza et al. (2006), which was 63%.
The average time for the delivery of ARV drugs to 
the UDM, considered from the first working day of the 
month (when it is possible to make a monthly request 
for drugs via the SICLOM software) was of 25.2 days 
(SD=0.25). One can consider this a very long-term 
delivery as, although the SICLOM software considers 
calculating a sufficient stock for two months, the request 
always involves the amount needed to complete the 
inventory required to meet that period. As there are 
variations in consumption in some months, the amount of 
a specific drug may be insufficient in this 25-day period, 
increasing the risk of shortages.
COMPONENT: DISPENSING
Code Indicator / Name Calculation Standard Source Average Result
C3
Percentage of prescriptions 
in accordance with the 
Brazilian Current consensus 
for treatment of patients with 
HIV/ AIDS
Prescriptions acceptable 
number / number of 
prescriptions analyzed
100% Oliveira et al., 2002 100%
C4 Percentage of patients with guidance in the dispensation
Number of targeted patients / 
Number of patients
Above 40% Luiza et al., 2006 25,3%
C5 Percentage of patients with correct use of medicines
Number of patients with 
correct use / number of 
patients
Above 75% Luiza et al., 2006 94,8%
COMPONENT: QUALIFICATION
D1 Percentage of Pharmacists with training in HIV/ AIDS
Number of trained 
pharmaceutical / 
pharmaceutical number (%)
100% Luiza et al., 2006 100%
D2 Percentage of Dispensers with training in HIV/ AIDS
Number of trained dispensers / 
dispensers number (%)
100% Luiza et al., 2006 46,7%
D3
Percentage of UDM that have 
valid sources of information 
about medicines
Use the UDM or not valid 
sources of information about 
medicines
100% Luiza et al., 2006 33,3%
D4
Percentage of workload of the 
pharmacist dedicated to the 
program HIV/AIDS
Number of hours available 
of Pharmacist (s) Number of 
hours care program for HIV 
AIDS Unit (%)
100% Adaptaded of Brasil, 2008 24,7%
TABLE I - List of indicators used and results obtained (average results for UDM) (cont.)
TABLE II - Matrix for value judgment of quality of the 
pharmaceutical services in HIV/AIDS in Niterói, Brazil
Percentage Obtained Degree Of Quality
≥ 80 Optimal
60 a 79,9 Good
40,0 a 59,9 Regular
≤ 39,9 Bad
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All UDM, even the smallest ones, reported having 
ARV drugs for the immediate treatment of any new 
patient. These results are consistent with the patterns 
shown by the evaluation of the AIDS Program of the 
Brazilian Department of Health (Qualiaids), in 2010, that 
showed only 73.1% of the UDM surveyed had ARV drugs 
available for initial treatment. (Brasil, 2008a)
Regarding the availability of time for changing of 
drugs in special situations (treatment failure or unusual 
drugs), the general average seen (10.6 days) was above 
the one considered ideal by the experts who took part 
in this work. It is important to note that this indicator 
was suggested due to difficulties to provide medicines to 
patients in the case of therapeutic exchanges.
The average score for the indicator measuring the 
Good Storage Practices (GSP) was 73.7% (SD=11.4), which 
shows that storage conditions varied greatly amongst the 
UDM. Some had good storage conditions, while others 
were quite poor in terms of physical structure, without even 
a proper and exclusive place for the service of Pharmacy, 
which shared it with other sectors of the work. Other studies 
also found similar results (Brasil, 2005; Luiza et al., 2006; 
De Bernardi, Bierbach, Thomé, 2006; Correia, Coelho, 
2009). Oliveira et al. (2002), however, found lower values. 
During the period of data collection, no drug with an expired 
validity date was found in the UDM.
The variability pointers for stocks of ARV drugs 
found an average percentage change in the inventory of 
14.8% (SD=5.5) and the percentage in the number of items 
ranging above 5% in the respective inventory was, on 
average, 33.6% (SD=13.3). This suggests the occurrence 
of errors, whether in inventory control, including the 
handling of the computerized system or, what is more 
serious, in the dispensing process. The origin of these 
differences was not the object of this work and their 
identification requires a higher level of detail.
The average score for the indicator of Good Practice 
Dispensing (GPD) was 51.2% (SD = 19.1), which also 
shows a great variation in the result between UDM, but 
with a relatively low average value, indicating a need 
for programmatic interventions to improve medicine 
dispensing practices. 
It should also be pointed that although all UDM 
declare that pharmacists supervise the dispensing process, 
only four reported some level of pharmaceutical care 
provided, and there is no kind of pharmaco-therapeutic 
monitoring. More worrying is the fact that the consensus 
guidelines of the Department of Health (Brasil, 2008; 
Brasil, 2013) are available for consultation at only two 
UDM and that only one had another source of information 
beyond the consensus itself to support patient care.
The non-participation of pharmacists in adherence 
groups and, in some UDM, the lack of control of absentees 
could also indicate a low insertion of the pharmacist in 
interdisciplinary health care team. 
Only two UDM reported using SICLOM’s 
dispensing processes at the exact moment the ARV 
drug is delivered to the patient. We should point that the 
national AIDS programme suggests that it should be used 
to support dispensing, especially because the system 
allows, besides verifying the adequacy of the date of 
withdrawal of the drug, to detect potential prescription 
errors (unauthorized associations, for example) at the exact 
time of dispensing of drugs.
All ARV prescriptions dispensed at the UDM 
in July 2013 were evaluated for their consistency 
with the Brazilian consensus in use at the date of data 
collection (Brasil, 2008). None of the prescriptions 
analyzed contained dosage problems or contraindicated 
associations. (Brasil, 2008; Brasil, 2013). However, it 
is important to emphasize that a deeper analysis of the 
therapeutic approach was not in the objectives of this 
work, and only absolute contraindications in ARV drug 
combinations were considered.
Of the 154 patients interviewed, 39 (25.3%) reported 
being instructed, at some point, by the UDM pharmacy, 
and 146 patients (94.8%) demonstrated a correct use of 
the medication. The average age of patients was 45.5 
years (SD=17.5). There was no significant difference in 
response according to gender in any of the two questions, 
using the chi square Yates corrected, with one degree of 
freedom (p=1.2688 and 1.3395 respectively).
The results were similar to those obtained by Luiza 
et al., (2006), where on average only 15.9% of users 
considered they received some guidance about their 
medicines at the pharmacy. In this same study 84.0% of 
patients knew the basic usage of the prescription drugs. 
Other studies have found a value of 77.6% of users with 
basic knowledge about medicines (Brasil, 2005).
Despite the low percentage of patients that said they 
had been advised at the pharmacy at some time during 
their treatment, the majority (94.8%) correctly described 
the use of the ARV drugs, at least in matters related to the 
identification of drug dosages and schedules. This fact 
can be explained by the typical characteristics of the HIV/
AIDS programme that encourage increased involvement 
of all the professionals involved in the issues related to 
adherence to treatment. A common response from patients 
was that there was no great need for information from the 
pharmacy as the doctor and other professionals had already 
oriented them.
All pharmacists in all the UDM were trained at some 
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point in pharmaceutical services in the treatment of AIDS. 
An important issue is that, according to some reports (four 
out of six pharmacists interviewed), the frequency of 
training has declined in recent years.
An interesting point is that the skills that involve 
more basic issues, such as AIDS and adherence counselling, 
were done during the older training program, usually at the 
start of the program at the UDM. Perhaps this explains the 
fact that some of the pharmacists more recently engaged 
in the AIDS program (41.7%) were not trained in those 
aspects.
In relation to the training of non-pharmacists that 
participate of the dispensing process, only an average 
47,0% were trained (SD=37.6). It is important to note the 
fact that in some UDMs, although those people had been 
trained to use the SICLOM software, its use in routine 
work is low.
Only two UDM (33%) reported they have their 
own valid sources of information on medicines. Beyond 
that, some pharmacists did not receive training in AIDS 
therapeutic issues. Both the lack of access to sources 
of information as well as the deficiency in training can 
compromise medication therapeutic management. It is 
worth mentioning that the two UDM that have information 
sources are the same that reported having a recent copy of 
the latest AIDS therapeutical consensus.
Regarding the number of hours available from 
the pharmacist, as most UDM work on non-exclusive 
outpatient pharmacies for HIV/AIDS patients, pharmacists 
were asked to estimate how many hours per week are 
dedicated to the AIDS/HIV program. This value was 
divided by the total number of hours in which AIDS 
patients are cared for at the UDM. The overall average 
score for this indicator was of only 24.7% (SD=13.2), 
indicating the workload of pharmacists dedicated to the 
program.
Results of the assessment of Pharmaceutical 
Services Components
Table III show the overall result for each component 
of the pharmaceutical services.
It can be seen that only the component Distribution 
had a good result, basically because of the good percentage 
obtained by drug availability indicators. In contrast, the 
result for component Qualification had a poor result, which 
suggests the need for the further training of pharmacists 
and dispensers mainly. The other components were 
considered reasonable, which will also require an effort 
to improve, especially because they are the main activities 
of the pharmacists.
Overall result of the evaluation 
Table IV shows the overall result of the evaluation 
per UDM and the overall result for the city, with a 
50.3% grade for the quality of pharmaceutical services, 
considered only regular according to the parameters 
presented in Table II. The result is lower than that obtained 
by Oliveira et al., (2002) who found 89% in programme 
implementation. 
It is important to note that, in the 2002, the program 
was being implemented and SICLOM was not even 
being used yet. Besides that, Oliveira et al., (2002) 
published their study before or at the beginning of the 
implementation of the National Pharmaceutical Assistance 
policy. Nowadays, in one hand, SICLOM is a reality that 
facilitates some work processes, especially in dispensing 
drugs, but the complexity of pharmaceutical care processes 
in HIV/AIDS is higher. It is also important to emphasize 
that in the current reality, it was observed a good 
availability of drugs but the pharmacist’s work processes 
have not reached satisfactory levels.
CONCLUSION 
The results obtained in this work allowed answering 
the evaluative questions, observing that the degree of 
TABLE III - Overall result for the assessment for the Health 
Foundation of Niterói city (HFN) for pharmaceutical services 
components 
Components Percentage
Distribuition 61,4
Storage 45,5
Dispensing 53,3
Qualification 30,0
TABLE IV - Quality degree of the pharmaceutical services in 
HIV/AIDS in the Health Foundation of Niterói city (FMS) 
(value judgment) 
UDM Value Quality degree
UDM2 56,4 Regular
UDM3 61,8 Good
UDM4 44,2 Regular
UDM5 50,3 Regular
UDM6 49,1 Regular
UDM7 70,9 Good
FMS 50,3 Regular
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quality of the pharmaceutical services for HIV/AIDS 
patients in Niterói, was on average 50%. However, there 
was a heterogeneous scenario between the UDMs, with 
two of them showing a good quality degree.
Access to drugs was considered satisfactory in 
relation to ARV medication, and only reasonable in 
relation to drugs for opportunistic infections. But the 
concept of access includes the availability and quality of 
the information. Thus, one can consider that the access was 
only partial, as the availability of drugs was not followed 
by a good compliance and quality of pharmaceutical care 
services.
The assessment offered subsidies to detect strengths 
and weaknesses in the pharmaceutical services. Among the 
strengths, the availability of ARVs stands out, as well as 
the absence of expired medications and of prescriptions 
at odds with the HIV/AIDS treatment consensus, besides 
well-targeted patients in the use of ARV drugs. As 
weaknesses, the low levels of compliance against criteria 
of good pharmaceutical practices, both in transport, 
storage and dispensing medications are highlighted, as 
well as the low use of the SICLOM program in the process 
of dispensation.
It is necessary, therefore to see an urgent improvement 
of the pharmacies’ infrastructural conditions at the non-
exclusive units of the program, in which, mostly, both 
local storage of medicines, and the space for medicine 
dispensing are limited and precarious. These changes 
should also include improving transport conditions, with 
the use of suitable transport vehicles.
Another important issue is the need to change the 
delivery logistics of ARV drugs for the city of Niterói, 
(which are set by the Brazilian Department of Health in 
conjunction with the State Government of Rio de Janeiro). 
This is to reduce the excessive time between the ARV 
drugs being requested by the city through SICLOM and 
the effective delivery of the products.
As already proposed in previous studies (Oliveira 
et al., 2002) it is essential to increase the number 
and frequency of training programs for pharmacists 
and dispensers, including periodic training on the 
SICLOM’s routine use, the AIDS disease in all of its 
aspects (diagnosis, epidemiology, treatment, etc.) and on 
pharmaceutical services in HIV/AIDS in particular.
Finally, it would be important to conduct studies to 
verify the possibility of reorganization of work processes 
related to dispensing activities, with most of the attention 
focused on the patient, such as pharmaceutical care 
deployment, or patient education/counselling activities 
that could improve the quality of therapeutic outcomes 
by increasing the adherence to treatment. These should 
include the possibility of physical and structural reforms in 
UDMs and a re-definition of the human resources needed 
to accomplish those goals.
The problems identified in this study are mostly 
not unique to the AIDS program, but reflect the lack 
of structural conditions of health facilities that affect 
program quality, including pharmaceutical services as a 
whole. Although the AIDS program has its own unique 
features which mainly reflect a greater availability of 
resources (medicines, equipment such as computers, etc.), 
the program cannot operate completely isolated from the 
context in which it functions.
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